Last reviewed · How we verify
bimatoprost 0.03% plus timolol 0.5%
bimatoprost 0.03% plus timolol 0.5% is a Small molecule drug developed by Allergan. It is currently FDA-approved. Also known as: GANFORT®.
At a glance
| Generic name | bimatoprost 0.03% plus timolol 0.5% |
|---|---|
| Also known as | GANFORT® |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
- Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan® (PHASE4)
- Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated (PHASE4)
- Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension (NA)
- Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension (PHASE4)
- Efficacy of Changing to DUOTRAV® From Prior Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bimatoprost 0.03% plus timolol 0.5% CI brief — competitive landscape report
- bimatoprost 0.03% plus timolol 0.5% updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about bimatoprost 0.03% plus timolol 0.5%
What is bimatoprost 0.03% plus timolol 0.5%?
bimatoprost 0.03% plus timolol 0.5% is a Small molecule drug developed by Allergan.
Who makes bimatoprost 0.03% plus timolol 0.5%?
bimatoprost 0.03% plus timolol 0.5% is developed and marketed by Allergan (see full Allergan pipeline at /company/allergan).
Is bimatoprost 0.03% plus timolol 0.5% also known as anything else?
bimatoprost 0.03% plus timolol 0.5% is also known as GANFORT®.
What development phase is bimatoprost 0.03% plus timolol 0.5% in?
bimatoprost 0.03% plus timolol 0.5% is FDA-approved (marketed).
Related
- Manufacturer: Allergan — full pipeline
- Also known as: GANFORT®
- Compare: bimatoprost 0.03% plus timolol 0.5% vs similar drugs
- Pricing: bimatoprost 0.03% plus timolol 0.5% cost, discount & access